Dynavax (DVAX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

DVAX Stock Forecast

Dynavax stock forecast is as follows: an average price target of $29.00 (represents a 127.27% upside from DVAX’s last price of $12.76) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

DVAX Price Target

The average price target for Dynavax (DVAX) is $29.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $29.00 to $29.00. This represents a potential 127.27% upside from DVAX's last price of $12.76.

DVAX Analyst Ratings

Buy

According to 3 Wall Street analysts, Dynavax's rating consensus is 'Buy'. The analyst rating breakdown for DVAX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Dynavax Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 28, 2024	Edward White	H.C. Wainwright	$29.00	$11.37	155.06%	127.27%
May 14, 2024	Paul Choi	Goldman Sachs	$20.00	$11.00	81.82%	56.74%

The latest Dynavax stock forecast, released on Jun 28, 2024 by Edward White from H.C. Wainwright, set a price target of $29.00, which represents a 155.06% increase from the stock price at the time of the forecast ($11.37), and a 127.27% increase from DVAX last price ($12.76).

Dynavax Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$24.50
Last Closing Price	$12.76	$12.76	$12.76
Upside/Downside	-100.00%	-100.00%	92.01%

In the current month, the average price target of Dynavax stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Dynavax's last price of $12.76. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 15, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 28, 2024	H.C. Wainwright	Buy	Buy	Hold
May 14, 2024	Goldman Sachs	Neutral	Neutral	Hold
May 14, 2024	H.C. Wainwright	Buy	Buy	Hold
Feb 24, 2023	JMP Securities	Market Outperform	Market Outperform	Hold
Sep 27, 2022	JMP Securities		Outperform	Initialise

Dynavax's last stock rating was published by H.C. Wainwright on Oct 15, 2024. The company gave DVAX a "Buy" rating, the same as its previous rate.

Dynavax Financial Forecast

Dynavax Revenue Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$69.51M	$60.25M	$46.92M	$184.49M	$167.74M	$256.46M	$113.99M	$195.07M	$108.27M	$52.77M	$83.33M	$19.55M	$13.41M
Avg Forecast	$106.32M	$133.66M	$126.67M	$107.33M	$90.49M	$112.42M	$105.29M	$86.89M	$79.70M	$95.01M	$87.00M	$69.83M	$71.71M	$84.17M	$76.04M	$54.98M	$52.73M	$60.30M	$48.39M	$38.58M	$179.60M	$159.41M	$150.99M	$154.29M	$208.87M	$58.22M	$41.60M	$59.11M	$13.06M	$9.44M
High Forecast	$107.53M	$135.19M	$128.12M	$108.55M	$91.52M	$113.70M	$106.50M	$87.88M	$80.61M	$96.10M	$87.99M	$70.63M	$73.68M	$84.74M	$76.04M	$54.98M	$54.73M	$66.01M	$48.94M	$39.02M	$181.65M	$159.41M	$150.99M	$154.29M	$208.87M	$58.22M	$41.60M	$59.11M	$13.06M	$9.44M
Low Forecast	$104.68M	$131.60M	$124.71M	$105.67M	$89.09M	$110.68M	$103.67M	$85.54M	$78.47M	$93.55M	$85.66M	$68.75M	$69.75M	$83.60M	$76.04M	$54.98M	$50.71M	$58.29M	$47.64M	$37.99M	$176.82M	$159.41M	$150.99M	$154.29M	$208.87M	$58.22M	$41.60M	$59.11M	$13.06M	$9.44M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	3	1	1	1	2	4	2	2	1	1	1	1	2	2	2	2	2	3
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.15%	1.25%	1.22%	1.03%	1.05%	1.70%	0.74%	0.93%	1.86%	1.27%	1.41%	1.50%	1.42%

Dynavax's average Quarter revenue forecast for Dec 23 based on 2 analysts is $52.73M, with a low forecast of $50.71M, and a high forecast of $54.73M. DVAX's average Quarter revenue forecast represents a -24.15% decrease compared to the company's last Quarter revenue of $69.51M (Sep 23).

Dynavax EBITDA Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	3	1	1	1	2	4	2	2	1	1	1	1	2	2	2	2	2	3
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$5.12M	$-3.40M	$-9.72M	$69.66M	$68.91M	$130.41M	$34.47M	$102.37M	$-24.99M	$9.35M	$7.36M	$-8.90M	$10.94M
Avg Forecast	$-27.96M	$-35.15M	$-33.31M	$-28.22M	$-23.80M	$-29.56M	$-27.69M	$-22.85M	$-20.96M	$-24.99M	$-22.88M	$-18.36M	$-18.86M	$-22.13M	$-20.00M	$54.67M	$-13.86M	$-15.86M	$-12.73M	$-10.15M	$109.17M	$-37.40M	$-35.43M	$39.29M	$-49.01M	$-13.66M	$-9.76M	$16.56M	$-3.07M	$-2.21M
High Forecast	$-27.53M	$-34.61M	$-32.80M	$-27.79M	$-23.43M	$-29.11M	$-27.26M	$-22.49M	$-20.63M	$-24.60M	$-22.52M	$-18.08M	$-18.34M	$-21.98M	$-20.00M	$65.61M	$-13.33M	$-15.33M	$-12.53M	$-9.99M	$131.01M	$-37.40M	$-35.43M	$47.15M	$-49.01M	$-13.66M	$-9.76M	$19.88M	$-3.07M	$-2.21M
Low Forecast	$-28.28M	$-35.55M	$-33.69M	$-28.54M	$-24.07M	$-29.90M	$-28.00M	$-23.11M	$-21.20M	$-25.27M	$-23.14M	$-18.57M	$-19.37M	$-22.28M	$-20.00M	$43.74M	$-14.39M	$-17.36M	$-12.87M	$-10.26M	$87.34M	$-37.40M	$-35.43M	$31.43M	$-49.01M	$-13.66M	$-9.76M	$13.25M	$-3.07M	$-2.21M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.32%	0.27%	0.96%	0.64%	-1.84%	-3.68%	0.88%	-2.09%	1.83%	-0.96%	0.44%	2.90%	-4.94%

2 analysts predict DVAX's average Quarter EBITDA for Dec 23 to be $-13.86M, with a high of $-13.33M and a low of $-14.39M. This is -371.01% lower than Dynavax's previous annual EBITDA (Sep 23) of $5.12M.

Dynavax Net Income Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	3	1	1	1	2	4	2	2	1	1	1	1	2	2	2	2	2	3
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$14.29M	$3.43M	$-24.33M	$67.73M	$63.81M	$128.75M	$32.86M	$101.39M	$-28.43M	$4.47M	$891.00K	$-15.47M	$4.40M
Avg Forecast	$20.53M	$38.76M	$34.66M	$22.46M	$12.55M	$27.45M	$23.31M	$11.66M	$7.74M	$22.71M	$18.06M	$3.61M	$5.88M	$17.54M	$9.99M	$49.53M	$-1.63M	$-5.85M	$-14.37M	$45.03M	$106.41M	$45.83M	$35.14M	$35.60M	$98.86M	$3.86M	$-5.66M	$2.00M	$-37.84M	$-31.41M
High Forecast	$20.83M	$39.34M	$35.18M	$22.80M	$12.74M	$27.85M	$23.66M	$11.83M	$7.86M	$23.04M	$18.33M	$3.67M	$8.82M	$17.90M	$10.03M	$59.44M	$1.63M	$23.38M	$-14.09M	$54.04M	$127.70M	$45.83M	$35.14M	$42.72M	$98.86M	$3.86M	$-5.66M	$2.41M	$-37.84M	$-31.41M
Low Forecast	$20.12M	$37.98M	$33.96M	$22.01M	$12.30M	$26.90M	$22.85M	$11.42M	$7.58M	$22.25M	$17.70M	$3.54M	$1.47M	$17.18M	$9.96M	$39.63M	$-4.90M	$-40.92M	$-14.59M	$36.02M	$85.13M	$45.83M	$35.14M	$28.48M	$98.86M	$3.86M	$-5.66M	$1.60M	$-37.84M	$-31.41M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.45%	-0.24%	-0.54%	0.64%	1.39%	3.66%	0.92%	1.03%	-7.36%	-0.79%	0.44%	0.41%	-0.14%

Dynavax's average Quarter net income forecast for Dec 23 is $-1.63M, with a range of $-4.90M to $1.63M. DVAX's average Quarter net income forecast represents a -111.44% decrease compared to the company's last Quarter net income of $14.29M (Sep 23).

Dynavax SG&A Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	3	1	1	1	2	4	2	2	1	1	1	1	2	2	2	2	2	3
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$38.05M	$37.07M	$36.54M	$31.02M	$32.04M	$36.18M	$32.17M	$29.22M	$26.93M	$21.58M	$22.42M	$17.84M	$29.24M
Avg Forecast	$104.19M	$130.99M	$124.13M	$105.18M	$88.68M	$110.17M	$103.19M	$85.15M	$78.10M	$93.11M	$85.26M	$68.43M	$70.28M	$82.48M	$74.52M	$48.50M	$51.67M	$59.09M	$47.42M	$37.81M	$31.17M	$156.22M	$147.97M	$34.85M	$204.69M	$57.05M	$40.77M	$50.45M	$12.80M	$9.25M
High Forecast	$105.38M	$132.48M	$125.55M	$106.38M	$89.69M	$111.43M	$104.36M	$86.12M	$79.00M	$94.18M	$86.23M	$69.21M	$72.20M	$83.04M	$74.52M	$58.20M	$53.64M	$64.69M	$47.96M	$38.24M	$37.40M	$156.22M	$147.97M	$41.82M	$204.69M	$57.05M	$40.77M	$60.54M	$12.80M	$9.25M
Low Forecast	$102.58M	$128.96M	$122.22M	$103.55M	$87.31M	$108.47M	$101.59M	$83.83M	$76.90M	$91.67M	$83.94M	$67.38M	$68.35M	$81.92M	$74.52M	$38.80M	$49.69M	$57.12M	$46.69M	$37.23M	$24.93M	$156.22M	$147.97M	$27.88M	$204.69M	$57.05M	$40.77M	$40.36M	$12.80M	$9.25M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.64%	0.78%	0.97%	1.00%	0.21%	0.24%	0.92%	0.14%	0.47%	0.53%	0.44%	1.39%	3.16%

Dynavax's average Quarter SG&A projection for Dec 23 is $51.67M, based on 2 Wall Street analysts, with a range of $49.69M to $53.64M. The forecast indicates a 35.78% rise compared to DVAX last annual SG&A of $38.05M (Sep 23).

Dynavax EPS Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	3	1	1	1	2	4	2	2	1	1	1	1	2	2	2	2	2	3
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$0.11	$0.03	$-0.19	$0.53	$0.50	$1.02	$0.26	$0.84	$-0.24	$0.04	$0.01	$-0.14	$0.04
Avg Forecast	$0.13	$0.25	$0.22	$0.15	$0.08	$0.18	$0.15	$0.08	$0.05	$0.15	$0.12	$0.02	$0.04	$0.11	$0.06	$-0.02	$-0.01	$-0.04	$-0.09	$-0.13	$0.41	$0.30	$0.23	$0.28	$0.64	$0.03	$-0.04	$-0.03	$-0.24	$-0.20
High Forecast	$0.13	$0.25	$0.23	$0.15	$0.08	$0.18	$0.15	$0.08	$0.05	$0.15	$0.12	$0.02	$0.06	$0.12	$0.06	$-0.02	$0.01	$0.15	$-0.09	$-0.13	$0.42	$0.30	$0.23	$0.28	$0.64	$0.03	$-0.04	$-0.03	$-0.24	$-0.20
Low Forecast	$0.13	$0.25	$0.22	$0.14	$0.08	$0.17	$0.15	$0.07	$0.05	$0.14	$0.11	$0.02	$0.01	$0.11	$0.06	$-0.02	$-0.03	$-0.26	$-0.09	$-0.13	$0.40	$0.30	$0.23	$0.28	$0.64	$0.03	$-0.04	$-0.03	$-0.24	$-0.20
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.91%	-0.29%	1.43%	1.29%	1.69%	4.48%	0.93%	1.31%	-9.60%	-1.09%	-0.40%	0.57%	-0.20%

According to 2 Wall Street analysts, Dynavax's projected average Quarter EPS for Dec 23 is $-0.01, with a low estimate of $-0.03 and a high estimate of $0.01. This represents a -109.60% decrease compared to DVAX previous annual EPS of $0.11 (Sep 23).

Dynavax Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
EBS	Emergent BioSolutions	$8.79	$51.50	485.89%	Buy
AQST	Aquestive Therapeutics	$3.85	$10.00	159.74%	Buy
IRWD	Ironwood Pharmaceuticals	$3.53	$8.50	140.79%	Buy
DVAX	Dynavax	$12.90	$29.00	124.81%	Buy
LNTH	Lantheus	$92.66	$155.00	67.28%	Buy
AMPH	Amphastar Pharmaceuticals	$40.85	$66.00	61.57%	Buy
ANIP	ANI Pharmaceuticals	$55.83	$79.00	41.50%	Buy
COLL	Collegium Pharmaceutical	$30.90	$42.33	36.99%	Buy
ALKS	Alkermes	$30.75	$37.50	21.95%	Hold
PCRX	Pacira BioSciences	$19.83	$23.75	19.77%	Hold
NBIX	Neurocrine Biosciences	$136.69	$156.14	14.23%	Buy
ITCI	Intra-Cellular Therapies	$86.96	$93.33	7.33%	Buy

DVAX Forecast FAQ

Is Dynavax a good buy?

Yes, according to 3 Wall Street analysts, Dynavax (DVAX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of DVAX's total ratings.

What is DVAX's price target?

Dynavax (DVAX) average price target is $29 with a range of $29 to $29, implying a 127.27% from its last price of $12.76. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Dynavax stock go up soon?

According to Wall Street analysts' prediction for DVAX stock, the company can go up by 127.27% (from the last price of $12.76 to the average price target of $29), up by 127.27% based on the highest stock price target, and up by 127.27% based on the lowest stock price target.

Can Dynavax stock reach $20?

DVAX's average twelve months analyst stock price target of $29 supports the claim that Dynavax can reach $20 in the near future.

What are Dynavax's analysts' financial forecasts?

Dynavax's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $395.09M (high $399.6M, low $388.99M), average EBITDA is $-104M (high $-102M, low $-105M), average net income is $74.97M (high $76.09M, low $73.47M), average SG&A $387.18M (high $391.6M, low $381.2M), and average EPS is $0.484 (high $0.491, low $0.475). DVAX's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $473.98M (high $479.39M, low $466.66M), average EBITDA is $-125M (high $-123M, low $-126M), average net income is $116.41M (high $118.14M, low $114.08M), average SG&A $464.49M (high $469.79M, low $457.31M), and average EPS is $0.752 (high $0.763, low $0.737).

Did the DVAX's actual financial results beat the analysts' financial forecasts?

Based on Dynavax's last annual report (Dec 2022), the company's revenue was $722.68M, beating the average analysts forecast of $644.29M by 12.17%. Apple's EBITDA was $298.23M, beating the average prediction of $75.63M by 294.34%. The company's net income was $293.16M, beating the average estimation of $222.98M by 31.47%. Apple's SG&A was $131.41M, missing the average forecast of $370.21M by -64.50%. Lastly, the company's EPS was $2.91, beating the average prediction of $1.22 by 139.31%. In terms of the last quarterly report (Sep 2023), Dynavax's revenue was $69.51M, beating the average analysts' forecast of $60.3M by 15.28%. The company's EBITDA was $5.12M, missing the average prediction of $-15.857M by -132.26%. Dynavax's net income was $14.29M, missing the average estimation of $-5.846M by -344.51%. The company's SG&A was $38.05M, missing the average forecast of $59.09M by -35.60%. Lastly, the company's EPS was $0.11, missing the average prediction of $-0.0378 by -391.31%